about
Cytoskeletal Regulation of Inflammation and Its Impact on Skin Blistering Disease Epidermolysis Bullosa AcquisitaPrevalence of pemphigus and pemphigoid autoantibodies in the general populationEfomycine M, a new specific inhibitor of selectin, impairs leukocyte adhesion and alleviates cutaneous inflammation.Management of cutaneous type IV hypersensitivity reactions induced by heparin.Incidence and causes of heparin-induced skin lesionsTherapeutic use of heparin beyond anticoagulation.Low allergenic potential with fondaparinux: results of a prospective investigation.Application, tolerance and safety of fondaparinux therapy in a German hospital: a prospective single-centre experience.Heparin-induced skin lesions.High incidence of heparin-induced allergic delayed-type hypersensitivity reactions in pregnancy.Nadroparin carries a potentially high risk of inducing cutaneous delayed-type hypersensitivity responses.Mechanisms of Autoantibody-Induced Pathology.Pathogenicity of autoantibodies in anti-p200 pemphigoid.Aberrant expression and secretion of heat shock protein 90 in patients with bullous pemphigoidPersistent autoantibody-production by intermediates between short-and long-lived plasma cells in inflamed lymph nodes of experimental epidermolysis bullosa acquisitaSkin microbiota-associated inflammation precedes autoantibody induced tissue damage in experimental epidermolysis bullosa acquisita.Spatial distribution of 8-methoxypsoralen penetration into human skin after systemic or topical administrationDissecting genetics of cutaneous miRNA in a mouse model of an autoimmune blistering diseaseLymphocyte trafficking to inflamed skin--molecular mechanisms and implications for therapeutic target molecules.Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of FcγRIIB and dectin-1.Structural requirements of heparin and related molecules to exert a multitude of anti-inflammatory activities.P-selectin: a common therapeutic target for cardiovascular disorders, inflammation and tumour metastasis.Clinical presentation, pathogenesis, diagnosis, and treatment of epidermolysis bullosa acquisitaAnimal models for autoimmune bullous dermatoses.Emerging treatments for pemphigoid diseases.Animal models to investigate pathomechanisms and evaluate novel treatments for autoimmune bullous dermatoses.Immune mechanism-targeted treatment of experimental epidermolysis bullosa acquisita.Epidermolysis Bullosa Acquisita: From Pathophysiology to Novel Therapeutic Options.Discovering potential drug-targets for personalized treatment of autoimmune disorders - what we learn from epidermolysis bullosa acquisita.Signalling and targeted therapy of inflammatory cells in epidermolysis bullosa acquisita.Analysis of serum markers of cellular immune activation in patients with bullous pemphigoid.IL-10 mediates plasmacytosis-associated immunodeficiency by inhibiting complement-mediated neutrophil migration.In vivo enzymatic modulation of IgG antibodies prevents immune complex-dependent skin injury.Meeting Report of the Pathogenesis of Pemphigus and Pemphigoid Meeting in Munich, September 2016.Clinical features and diagnosis of epidermolysis bullosa acquisita.Metabolite analysis distinguishes between mice with epidermolysis bullosa acquisita and healthy mice.Platelet, not endothelial, P-selectin expression contributes to generation of immunity in cutaneous contact hypersensitivity.Mapping of B cell epitopes on desmoglein 3 in pemphigus vulgaris patients by the use of overlapping peptides.Generation of antibodies of distinct subclasses and specificity is linked to H2s in an active mouse model of epidermolysis bullosa acquisita.Oligonucleotides suppress IL-8 in skin keratinocytes in vitro and offer anti-inflammatory properties in vivo.
P50
Q26740099-D21A73D8-4723-466F-90E5-BB159559C6A2Q28647292-26607DB3-9D64-4495-8577-D045B2469BE0Q30684054-3898A80F-3506-40D3-B7BB-6D140E0A380DQ33373160-C3FB0B03-2AC9-4749-9C74-F502D30ACCF7Q33386398-AEB183F6-5151-49CB-BFAC-FBF231348437Q33387579-31FD2268-FDFA-4436-861E-E9A47C7A3F37Q33391886-EFED424C-45C6-4D44-A28C-8734D3EE92E1Q33396169-255D17F5-7FB8-4F64-9B49-157B1B362EF4Q33401479-DF07A361-208A-4363-BAA6-95C451D70F78Q33408125-201DF9FD-4181-43FC-8CB8-A0D264489F4BQ33440138-2AF3B3C0-3F77-4497-937F-0E8F3CDCA33BQ33740580-DF7A370B-73DF-4482-8F37-9D2A201D52C6Q34388189-C36184AA-3498-4AE9-B898-2476C9D0AF53Q34923028-B3518694-76A0-4594-A3B9-2975B696178BQ35080528-0A0639F7-A131-44F0-A0E4-6B14C8E740FDQ35765070-677CFAEA-EDEB-4DCC-A307-DF80624DF47AQ35804157-CC3E6A75-F83F-485E-BF75-6DB578360F0CQ35924242-AF633117-01EC-48E0-A441-86AC2185BEC8Q36150816-236EB514-9793-4478-A619-1C8EFFD34911Q36380184-9CCA1E6E-6D9B-4DFF-B2B4-BC89B6D93D0AQ36612244-A8A6F7FE-4859-4AC2-B3BE-D08AF2723375Q36897359-C7CE70B8-8FC5-401B-9B94-C5B4947E9532Q37055162-F65B964E-7804-4C80-B922-D8A2D36AA559Q37585522-BB9CAC9B-A85E-4502-98E3-6FE8AE620776Q38119798-DF933154-9E54-4417-A681-1BCF815C4559Q38380510-F48523F3-C3AC-4CED-A709-158A7A53B89DQ38608315-8D3C0C09-D005-421A-9A1F-A5634FDB2E3CQ38695599-26D6642A-32F0-4BE3-8D61-2BA1BF53DC1BQ38720806-C467F536-F755-42B3-A2A6-2B3636BF5CC8Q38749755-D2C41DD6-6A90-44F9-9CA4-71724A01243DQ38788350-5B9B732E-6CF7-4E0B-BAEC-8F9949BB3E52Q38812873-B3B536CB-20C7-4318-BF4E-FFE96633CFCCQ38832411-B122FEED-FD0F-4102-9F8B-5906C75A2AC0Q38846434-4E1C6B20-B8EF-4A31-B64E-4B83081A4C34Q38942490-BF16DCDD-33FF-49A8-AFFE-02F7CE204497Q39396600-8F07F65B-E171-4B51-B404-639E2CC77DA1Q39403266-B3CFF0EF-D336-43E9-AE1F-DCB477D75E6BQ39409686-6991957B-97CD-4E9D-AB7A-96C7D735EE4CQ39846263-9503F5DA-B0B3-4A19-8D82-8595BDA45A10Q40202255-5608F2B0-A17B-4005-9059-3E56A24709A6
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Ralf J. Ludwig
@ast
Ralf J. Ludwig
@en
Ralf J. Ludwig
@es
Ralf J. Ludwig
@nl
Ralf J. Ludwig
@sl
type
label
Ralf J. Ludwig
@ast
Ralf J. Ludwig
@en
Ralf J. Ludwig
@es
Ralf J. Ludwig
@nl
Ralf J. Ludwig
@sl
prefLabel
Ralf J. Ludwig
@ast
Ralf J. Ludwig
@en
Ralf J. Ludwig
@es
Ralf J. Ludwig
@nl
Ralf J. Ludwig
@sl
P1053
A-2629-2008
P106
P1153
56353620900
P21
P214
3571152822004701040002
P2798
P31
P3829
P496
0000-0002-1394-1737
P734
P735
P7859
viaf-3571152822004701040002